Baidu
map

Plos Medicine:可控风险因素和阿尔兹海默症的关联

2015-06-26 佚名 生物谷

全球存在大约四千万老年痴呆症患者,而且数量还有增加的趋势,据估计到2050年全球将会有1.5亿老年痴呆患者。这些老年患者往往表现为记忆力下降,交流障碍和认知功能障碍。在这些老年痴呆患者中,最常见的是阿尔兹海默症(AD),大约占到60%-70%。研究者们一直在试图寻找AD的成因,尤其是那些可能的可控风险因素,因为通过控制这些因素可能可以降低AD的发病率。流行病学的研究已经发行了几种潜在的风险因素,例

全球存在大约四千万老年痴呆症患者,而且数量还有增加的趋势,据估计到2050年全球将会有1.5亿老年痴呆患者。这些老年患者往往表现为记忆力下降,交流障碍和认知功能障碍。在这些老年痴呆患者中,最常见的是阿尔兹海默症(AD),大约占到60%-70%。研究者们一直在试图寻找AD的成因,尤其是那些可能的可控风险因素,因为通过控制这些因素可能可以降低AD的发病率。流行病学的研究已经发行了几种潜在的风险因素,例如高血压、高血脂、肥胖和吸烟等。然而,具体的相关关系或者谁为因谁为果,还是很不清楚。近期Plos Medicine发文定量讨论了这些风险因素和AD的因果关系。作者使用孟德尔遗传概率分析的方法,试图探讨了这些风险因素和阿尔兹海默症间的因果关系。

在这种孟德尔遗传概率分析法中,因果关系是通过推测不同风险因素相关的遗传突变的效应得到的。这些遗传突变体是与我们感兴趣的风险因素相关的。正是因为这些突变体是通过遗传随机获得的,它们会倾向于有序,而且它们与反向的因果关系也是无关联的。例如,我们认为高血压可能实际上会导致AD,那么那些会影响着高血压的遗传突变也会影响着AD的发病率;如果说相反地,是AD导致了高血压,那么会影响着高血压的遗传突变并不会影响AD的发病风险。

在国际阿尔兹海默基因组计划的数据库中,研究人员们分析了17008位AD患者和37154位正常老年人的基因组数据,他们重点检测了单核酸位点多态性(SNP,一种遗传突变体的形式)的发生率,来预测风险因素对AD发病的影响。研究发现,更高的动脉收缩压会导致较低的AD发病风险;吸烟的数量也与低AD发病率相关联。其他的风险因素(肥胖和高血脂)与AD的风险不明确。这个结果与流行病学研究存在冲突。

为什么高血压会引起低AD发病率呢?一种可能的原因是,这些高血压患者会接受药物治疗。这些治疗高血压的药物,很可能是导致较低AD的首要因素。因为这个研究的数据全部来自欧洲人,因此对其他族群可能需要进一步研究。研究者还提到了,因为高血压会引起心血管疾病,因此他们并不鼓励通过提高血压来降低患AD的风险。未来对于抗高血压药物对AD发病率的影响还需要深入的研究。

原始出处:

Søren D. Østergaard, Shubhabrata Mukherjee, Stephen J. Sharp et al.Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study.PLOS Medicine, June 16, 2015.DOI: 10.1371/journal.pmed.1001841

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1773493, encodeId=c9af1e73493dc, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Fri Jan 01 18:59:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858613, encodeId=5aed1858613b9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Apr 18 12:59:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29841, encodeId=e226298419d, content=期待更好更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 15:06:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402656, encodeId=93b61402656d3, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577427, encodeId=63fb15e7427bd, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606530, encodeId=b2e71606530a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29588, encodeId=4af92958800, content=到目前为止还没有一个真正意义上的老年性痴呆的风险因素未来还需要进一步的探索另外各种不同的风险因素之间的交互作用也是研究的热点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Jun 26 14:10:00 CST 2015, time=2015-06-26, status=1, ipAttribution=)]
    2016-01-01 kalseyzl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1773493, encodeId=c9af1e73493dc, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Fri Jan 01 18:59:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858613, encodeId=5aed1858613b9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Apr 18 12:59:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29841, encodeId=e226298419d, content=期待更好更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 15:06:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402656, encodeId=93b61402656d3, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577427, encodeId=63fb15e7427bd, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606530, encodeId=b2e71606530a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29588, encodeId=4af92958800, content=到目前为止还没有一个真正意义上的老年性痴呆的风险因素未来还需要进一步的探索另外各种不同的风险因素之间的交互作用也是研究的热点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Jun 26 14:10:00 CST 2015, time=2015-06-26, status=1, ipAttribution=)]
    2016-04-18 jeanqiuqiu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1773493, encodeId=c9af1e73493dc, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Fri Jan 01 18:59:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858613, encodeId=5aed1858613b9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Apr 18 12:59:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29841, encodeId=e226298419d, content=期待更好更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 15:06:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402656, encodeId=93b61402656d3, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577427, encodeId=63fb15e7427bd, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606530, encodeId=b2e71606530a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29588, encodeId=4af92958800, content=到目前为止还没有一个真正意义上的老年性痴呆的风险因素未来还需要进一步的探索另外各种不同的风险因素之间的交互作用也是研究的热点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Jun 26 14:10:00 CST 2015, time=2015-06-26, status=1, ipAttribution=)]
    2015-06-29 owlhealth

    期待更好更多研究

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1773493, encodeId=c9af1e73493dc, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Fri Jan 01 18:59:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858613, encodeId=5aed1858613b9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Apr 18 12:59:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29841, encodeId=e226298419d, content=期待更好更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 15:06:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402656, encodeId=93b61402656d3, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577427, encodeId=63fb15e7427bd, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606530, encodeId=b2e71606530a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29588, encodeId=4af92958800, content=到目前为止还没有一个真正意义上的老年性痴呆的风险因素未来还需要进一步的探索另外各种不同的风险因素之间的交互作用也是研究的热点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Jun 26 14:10:00 CST 2015, time=2015-06-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1773493, encodeId=c9af1e73493dc, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Fri Jan 01 18:59:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858613, encodeId=5aed1858613b9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Apr 18 12:59:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29841, encodeId=e226298419d, content=期待更好更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 15:06:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402656, encodeId=93b61402656d3, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577427, encodeId=63fb15e7427bd, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606530, encodeId=b2e71606530a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29588, encodeId=4af92958800, content=到目前为止还没有一个真正意义上的老年性痴呆的风险因素未来还需要进一步的探索另外各种不同的风险因素之间的交互作用也是研究的热点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Jun 26 14:10:00 CST 2015, time=2015-06-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1773493, encodeId=c9af1e73493dc, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Fri Jan 01 18:59:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858613, encodeId=5aed1858613b9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Apr 18 12:59:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29841, encodeId=e226298419d, content=期待更好更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 15:06:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402656, encodeId=93b61402656d3, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577427, encodeId=63fb15e7427bd, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606530, encodeId=b2e71606530a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29588, encodeId=4af92958800, content=到目前为止还没有一个真正意义上的老年性痴呆的风险因素未来还需要进一步的探索另外各种不同的风险因素之间的交互作用也是研究的热点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Jun 26 14:10:00 CST 2015, time=2015-06-26, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1773493, encodeId=c9af1e73493dc, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Fri Jan 01 18:59:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858613, encodeId=5aed1858613b9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Apr 18 12:59:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29841, encodeId=e226298419d, content=期待更好更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 15:06:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402656, encodeId=93b61402656d3, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577427, encodeId=63fb15e7427bd, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606530, encodeId=b2e71606530a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 27 23:59:00 CST 2015, time=2015-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29588, encodeId=4af92958800, content=到目前为止还没有一个真正意义上的老年性痴呆的风险因素未来还需要进一步的探索另外各种不同的风险因素之间的交互作用也是研究的热点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Jun 26 14:10:00 CST 2015, time=2015-06-26, status=1, ipAttribution=)]
    2015-06-26 medcardio

    到目前为止还没有一个真正意义上的老年性痴呆的风险因素未来还需要进一步的探索另外各种不同的风险因素之间的交互作用也是研究的热点。

    0

相关资讯

Radiology:成像测试可鉴定老年痴呆标志物

根据发表在《放射学》杂志上一项新的研究结果表示,大脑的蛋白质变性可能是阿尔茨海默病(AD)的早期特定类型标志,包括早发型阿尔兹海默症。 “阿尔茨海默氏症是一种灰质疾病”,医学博士Federica Agosta说,“然而,白质损害中起重要作用的是疾病是如何进展的。” 阿尔兹海默症是一种不可逆转的,缓慢破坏记忆力和思维能力的进行性大脑疾病。这种疾病的特点在整个大脑有异常蛋白质的沉积,并形成淀粉

Cell Reports:阿尔兹海默症治疗方法或可发生改变

老年痴呆症患者大脑的一个典型特征是存在不溶性的Tau蛋白质总量。鲁汶大学和杨森制药公司的科学家已经证明,这些Tau蛋白质总量的分布可促进大脑细胞之间的突触连接。这个消息非常重要,因为越来越多的关注集中在修复突触连接上,该方向可作为一种治疗神经退行性疾病如阿尔茨海默氏症的方法。事实上,人们普遍认为突触连接的断失会导致认知能力的丧失。Dieder Moechars(杨森制药公司)说:“从研究结果分析来

开玩笑!这个女博士三年发了45篇SCI!

博士三年可以完成哪些事情?有的小伙伴觉得发个三篇SCI已经非常不容易了!有的小伙伴觉得能完成毕业的指标就可以~今天,让我们来看看中国海洋大学的一位女博士的三年博士生涯,大伙儿都要加把劲啊! 你如法想象谭梦姗瘦小的身体里蕴藏着多大的力量,三年博士生活,谭梦姗发表了45篇SCI,其中第一作者和共同第一作者12篇,单篇最高影响因子10.11,第一作者累计影响因子52。课题“阿尔茨海默病发病的神

清华施一公院士PNAS再发突破性成果

人们普遍认为,阿尔茨海默病(俗称老年痴呆)主要起因于β淀粉样蛋白(Aβ)在大脑内的累积。γ-分泌酶可以切割β淀粉样前体蛋白生成Aβ,与阿尔茨海默病的发病密切相关,是预防和治疗这种疾病的潜在靶点,受到了研究者们的广泛关注。γ分泌酶的切割过程非常复杂,这与它的复杂结构和作用机制有关。与组分单一的其他膜蛋白不同,γ分泌酶包含四种组分:presenilin (PS1)、Pen-2、Aph-1和Nicast

J Neurosci:研究发现阿尔茨海默病潜在新病因

来自杜克大学的研究团队在国际期刊神经学杂志上发表了他们的研究发现。研究人员使用一种具有更接近人免疫系统的阿尔茨海默病小鼠,以便观察疾病早期的免疫变化。研究者发现应用一种小分子药物可以阻碍免疫细胞消耗精氨酸。在小鼠身上测试发现,它避免了出现神经斑和记忆消失等阿尔茨海默病特征。他们阐述他们的发现点不仅是新的阿尔茨海默病潜在病因,也是新的治疗靶点。来自杜克大学医学院的神经学家,资深作者Carol Col

PLOS MED:抗高血压药物治疗或降低AD风险

 阿尔茨海默病(AD)流行趋势正处于上升的趋势,已经造成了越来越大的社会和经济压力。流行病学研究已经证明了潜在的可以修改的风险因子可以作为靶点来预防AD。这些风险因子包括了2型糖尿病和血糖特征、高血压、肥胖、吸烟、缺少体育锻炼、抑郁、血脂紊乱和较低的受教育程度。据报道,全球范围内有大约三分之一的AD病例是归因于这些风险因子的。考虑到实施大规模的风险因子修改的随机临床试验有着较大的难度,有

Baidu
map
Baidu
map
Baidu
map